CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies
CD58 antigen was stably expressed in patients with r/r B-ALL after multiline therapies, including allo-HCT and CAR-T, indicating that it could still be a leukemic marker in heavily treated patients.
Authors
- Heyuan Feng
- Shuangyou Liu (ORCID: https://orcid.org/0000-0001-9982-7099)
- Jian Kang (ORCID: https://orcid.org/0000-0002-8697-0993)
- Yafeng Li (ORCID: https://orcid.org/0000-0002-7500-0959)
- Li Pan
- Xinjian Yu (ORCID: https://orcid.org/0000-0002-6279-1544)
Institutions
- Beijing Tongren Hospital (CN)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-04-20
- DOI
- https://doi.org/10.1093/ajcp/aqae166
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00